Biomarin Pharmaceutical(BMRN) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $82
Moomoo NewsMar 21 16:31 ET · Ratings
Insider Sale: GVP of $BMRN Sells 1,295 Shares
Quiver QuantitativeMar 20 19:45 ET
BioMarin Pharmaceutical (BMRN): Among Paul Singer's Latest Portfolio's Top Stock Picks
Yahoo FinanceMar 20 15:25 ET
BioMarin Presents New Data Demonstrating Favorable Safety And Strong Adherence In Real-World Clinical Practice With VOXZOGO In Children Under 3 With Achondroplasia At 2025 ACMG Annual Clinical Genetics Meeting
BenzingaMar 20 09:02 ET
10 Strong Performing Energy and Health Care Stocks as Markets Resume Sell-off
Seeking AlphaMar 18 12:03 ET
Piper Sandler Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $126
Moomoo NewsMar 17 19:32 ET · Ratings

Comments

Moomoo AI

Mar 25, 2024 20:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

1

Moomoo AI

Mar 7, 2024 21:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

1

Moomoo AI

Feb 8, 2024 22:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

1

Moomoo AI

Jan 18, 2024 20:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 22, 2023 00:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts

BMRN Biomarin Pharmaceutical

Trade Overview

Capital Trend

News

Comments

Market Insights